CancerAppy
Novel cancer therapeutic drugs
At CancerAppy, we specialize in cancer research, dedicated to discovering and developing new therapeutic targets. Our proprietary artificial intelligence methodology allows us to accelerate advancements in more effective cancer treatments
Driving innovation in breakthrough oncology treatments.
With our deep expertise in oncology and AI, we analyze vast amounts of multimodal data using advanced AI algorithms. This allows us to identify new therapeutic targets, discover lead compounds, understand their mechanisms of action, and explore potential drug combinations. Our technology also enables the development of next-generation antibody-drug conjugates (ADCs), driving more precise and effective cancer treatments.
We work in the early stage of the Drug Discovery Value Chain.
Our R&D Pipeline
At CancerAppy, we use AI-driven drug discovery to develop new cancer therapies, including novel ADCs (antibody-drug conjugates). Our pipeline moves from target discovery to preclinical development, bringing innovative treatments closer to patients.
News
Latest news about CancerAppy…
CPP21 – InsilicoPROTACs
Cancerappy, together with UCLM, has been awarded the grant from the CCP21 program for the development of nanomedicines (nanoPROTACs), with a total...
AI in drug discovery
Artificial intelligence (AI) has the potential to revolutionize the drug discovery process by accelerating the identification of novel drug...
In the early stages, 97% of drug development fails.
In the early stages, 97% of drug development fails. The discovery and development of a new cancer drug is a long, costly, and high-risk process. The...
Grant CPP2021-008597 funded by:
Grant TQ2020-011486 funded by:
Subvencionado por el CDTI
Somos cliente Enisa
